ClinicalTrials.gg
RecruitingNCT04832607TRACEUpdated Jul 18, 2025

Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

A Phase 3 interventional study of Multivirus (CMV, EBV, AdV)-specific T cells in AdV Infection, EBV Infection and CMV Infection, sponsored by Tobias Feuchtinger. Recruiting at 33 sites in 6 countries. Open to participants aged 2 Months and older. Per ClinicalTrials.gov, last updated 2025-07-18.

Sponsored by Tobias Feuchtinger · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Aug 2019, registered Mar 2021).
  • Started Aug 2019; still recruiting 7 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
149
Allocation
Randomized
Ages
2 Months and older
Sex
All
01

Study summary

Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality. Adoptive transfer of virus-specific T cells is an attractive approach to restore protective T-cell immunity in patients with refractory viral infections after allogeneic HSCT. The aim of this Phase III trial is to confirm efficacy of this treatment in children and adults.

Read the detailed description

For a growing number of patients suffering from various conditions as, e.g., haematological malignancies or diverse genetic disorders, haematopoietic stem cell transplantation (HSCT) or bone marrow transplantation offer the only possible curative options. However, HSCT is associated with three major risks: graft rejection, graft-versus-host disease (GvHD) and opportunistic, mostly viral, infections or reactivations resulting from delayed immune reconstitution. Delayed immune reconstitution, however, often is the direct result of the severe pre-transplantation conditioning treatment and T-cell depletion of the transplant necessary to fight the risks of graft rejection and GvHD. Therefore, the risk for life-threatening opportunistic, mostly viral, infections is increased in post-transplantation patients. The most common infections after HSCT are Cytomegalovirus (CMV), Epstein-Barr virus (EBV) and Adenovirus (AdV).

The standard treatment approach for viral infections/reactivations is chemotherapy which shows limited efficacy and does not restore immunity. Therefore, effective new treatment options are required for this condition.

Previous investigations have shown that sufficient T-cell immunity is essential for the control and prevention of viral reactivations and newly occurring infections after HSCT. The infusion of T-cells is therefore a promising new approach to treat immune-comprised patients. However, infusion with unselected T cells is associated with an increased risk for GvHD due to the high content of alloreactive T cells. A very promising approach to minimize this problem is to remove alloreactive T cells and enrich, isolate and purify virus-specific T cells.

This approach has been studied for nearly two decades and the data published up to date indicate that virus-specific T-cell responses after adoptive T-cell transfer protect against virus-related complications post HSCT and restore T-cell immunity, in particular for AdV-, CMV- and EBV-infections. Despite these promising results, virus-specific T-cell transfer is not yet translated into daily clinical practice due to the lack of prospective clinical trials confirming the efficacy of this treatment approach.

The overall goal of this Phase III, double-blind placebo-controlled study is to test efficacy of multivirus-specific T cells to bring this treatment method in clinical routine. Multivirus-specific T cells generated in this study will be directed against all three most common post-HSCT viral infections: AdV, CMV and EBV. Thus, T-cell immunity will be restored to fight and prevent new viral infections.

After an initial screening visit, patients eligible to participate in the study will be treated within 28 days after screening. Patients will be randomized in a 2:1 (treatment: placebo) ratio and receive a single infusion with either multivirus-specific T cells or placebo. Patients will be followed up on the day of treatment, 1 day after and 1, 2, 4, 8 and 15 weeks after treatment. Treatment success will be measured by assessing different parameters including symptoms, quality of life, viral load and T-cell immunity in blood samples.

Patients eligible to participate in this study are adult and paediatric patients who have received allogeneic stem cell transplantation and suffer from new or reactivated EBV, AdV or CMV infection refractory to standard antiviral treatment for two weeks. Patients from the six European countries Germany, Belgium, Netherlands, UK, France and Italy will be enrolled. In total 130 patients plus 19 screening failures are expected to participate in the study.

02

Conditions studied

  • AdV Infection
  • EBV Infection
  • CMV Infection
  • Stem Cell Transplant Complications
03

In context

Adenoviridae Infections

136 studies on the registry are indexed under Adenoviridae Infections; 34 are open to participants now.

This study's planned enrollment of 149 is above the median of 30 across 109 interventional studies indexed under Adenoviridae Infections.

Browse Adenoviridae Infections studies →

Lead sponsor

This is the only study on the registry with Tobias Feuchtinger as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult or paediatric patients (> 2 months of age) after stem cell transplantation (SCT) (no time restrictions apply) suffering from new or reactivated CMV or EBV or AdV infection to standard antiviral treatment for two weeks (defined as no decrease or insignificant decrease of less than 1log in viral load over two weeks) as confirmed by quantitative blood PCR analysis.
  2. Original HSCT-donor available with an immune response at least to the virus causing the therapy-refractory (=underlying) infection.
  3. Written given (patient or legal representative) prior to any study-related procedures.

Exclusion criteria

Exclusion Criteria:

  1. Patient with acute GvHD > grade II or extensive chronic GvHD at the time of IMP transfer
  2. Patient receiving (>1 mg/kg BW Prednisone equivalent) at Screening.
  3. Therapeutic donor lymphocyte infusion (DLI) from 4 weeks prior to IMP infusion until 8 weeks post IMP infusion. Prescheduled prophylactic DLI ≤3x105 T cells/kg BW in case of T-cell depleted is not considered an exclusion criterion.
  4. Patient with organ dysfunction or failure as determined by (patients >16 years) or Lansky (patients ≤16 years) score ≤30%
  5. Concomitant enrolment in another clinical trial interfering with the endpoints of this study
  6. Any medical condition which could compromise participation in the study according to the investigator's assessment
  7. Progression of underlying disease (disease that has led to the indication of HSCT, e.g. leukaemia) that will limit the life expectance below the duration of the study
  8. or experimental antiviral treatment other than Ganciclovir/Valganciclovir, Foscarnet, Cidofovir and Rituximab until 8 weeks after IMP Infusion or prophylactic Treatment other than Aciclovir or Letermovir throughout the study except approved by sponsor
  9. Known infection. In case patients do not have a negative HIV test performed within 6 months before enrolment in the study, HIV negativity has to be confirmed by a negative laboratory test.
  10. Female patient who is pregnant or breast-feeding. Female patient of (i.e. post menarche and not surgically sterilized) or male patient of not willing to use an effective method of from Screening until the last follow-up visit (FU6, Visit 8).

    Note: Women of childbearing potential must have a negative serum pregnancy test at study entry ≤7 days before IMP administration on Day 0. Acceptable birth control methods are hormonal oral contraceptive ('pill'), contraceptive injection or patch, intrauterine pessar or the combination of two barrier methods. The combination of female and male condomes is NOT acceptable. If the male partner is sterilized, no further contraceptive is required. Women of status (no menses for 12 months without an alternative medical cause) are also not required to use contraceptives during the study.

  11. Known to iron dextran
  12. Patients unwilling or unable to comply with the protocol or unable to give .
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
149 participants (estimated)

Study arms

  • Experimental
    Multivirus (CMV, EBV, AdV)-specific T cells

    Allogeneic CD4+ and CD8+ T lymphocytes ex vivo incubated with synthetic peptides of the viral antigens of Cytomegalovirus, Adenovirus and Epstein-Barr Virus Max dose: * HLA-matched (8/8) donors: 1.0 x 10e5 T cells/kg recipient BW * HLA-mismatched donors: 2.5 x 10e4 T cells/kg recipient BW Min. dose: \- 10 T cells/kg recipient BW

    Other: Multivirus (CMV, EBV, AdV)-specific T cells

  • Placebo comparator
    Sodium chloride

    Suspension of multivirus-specific T cells in 20 mL of 0.9% NaCl + 0.5% HSA

    Other: Multivirus (CMV, EBV, AdV)-specific T cells

Interventions

  • OtherMultivirus (CMV, EBV, AdV)-specific T cells

    Cell therapy product which is individually produced for each patient and administered via IV bolus injection.

06

What researchers measure

Primary outcomes

  1. Viral clearance

    Percentage of patients with viral clearance (defined as two consecutive negative PCRs) to determine efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantation

    Time frame: 8 weeks after treatment

  2. Disease Progression

    Percentage of patients with progression between Day 7 and Week 8 after T-cell Transfer to determine efficacy of multispecific T-cell transfer in patients with chemo-refractory viral infections after allogeneic stem cell transplantation

    Time frame: day 7 until week 8 after treatment

Secondary outcomes

  1. Incidence of acute GvHD

    Incidence of newly occurring acute GvHD grade I from Day 0 to Week 8 and Week 15.

    Time frame: 15 weeks after treatment

  2. Incidence of chronic GvHD

    Incidence of chronic GvHD from Day 7 to Week 8 and to Week 15 after treatment.

    Time frame: 15 weeks after treatment

  3. Time to newly occuring GvHD

    Time to newly occurring acute and chronic GvHD.

    Time frame: 15 weeks after treatment

  4. Severity of GvHD

    Severity of acute GvHD ≥ grade II until Week 8 and Week 15.

    Time frame: week 8 and 15 week after treatment

  5. Incidence of acute toxicity

    Acute maximum toxicity on the day of T-cell transfer evaluated by measuring vital signs prior to and at different times after the T-cell transfer from 1 hour prior to T-cell transfer to 4 hours post infusion.

    Time frame: 15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer

  6. Severity of acute toxicity

    Monitoring of adverse events infusion.

    Time frame: 15 minutes, 30 minutes, 2 hours and 4 hours post T-cell/placebo transfer

  7. Change in viral load of underlying viral infection

    Change in viral load of underlying viral infection as assessed by quantitative PCR analysis of peripheral blood; samples taken weekly from Day 7 to Week 8 after IMP transfer as compared to samples taken at Day 0.

    Time frame: 8 weeks after treatment

  8. Time to viral load change of underlying viral infection

    Time to 1 log change in viral load.

    Time frame: 15 weeks after treatment

  9. Percentage of viral decrease

    Percentage of patients with ≥1 log decrease in CMV, EBV or AdV viral load at Week 8.

    Time frame: 8 weeks after treatment

  10. Viral reactivations

    Number of reactivations of the underlying viral infection following initial viral clearance until end of follow-up.

    Time frame: 15 weeks after treatment

  11. Clinical response/resolution of symptoms of underlying viral infection

    Number of patients with reduction or clearance of clinical symptoms of underlyingviral infection from Day 7 to Week 8 after IMP transfer as compared to Day 0.

    Time frame: 8 weeks after treatment

  12. Overall survival

    Overall survival rate (OS): From Day 0 to end of follow-up.

    Time frame: 15 weeks after treatment

  13. Necessity of antiviral chemotherapy

    Number of days requiring antiviral chemotherapy after T-cell transfer from Day 7 to Week 8 after T-cell transfer.

    Time frame: Day 7 until Week 8

  14. Duration of antiviral chemotherapy

    Time to last administration of defined antiviral medication or switch to prophylactic treatment from Day 0 to Week 8 after IMP transfer.

    Time frame: 8 weeks after treatment

  15. Incidence of viral infections other than underlying viral infection

    Number of new viral reactivations (CMV, AdV or EBV) other than the underlying viral infection per patient as assessed by PCR analysis and clinical symptoms throughout the study to evaluate the putative prophylactic effect of the treatment.

    Time frame: 15 weeks

  16. Days of hospitalization

    Number of days hospitalized after IMP transfer from Day 7 to Week 8.

    Time frame: 8 weeks

  17. Life quality in adults

    EQ-5D for adult patients (≥18 years) at Screening and Week 8 to evaluate life quality in adults. A scale from 0 to 100 is used with 100 being best value and 0 the worst.

    Time frame: Screening and Week 8.

  18. Life quality in adults

    FACT-BMT for adult patients (≥18 years) at Screening and Week 8 to evaluate life quality in adults. The patients have to answer questions about their physicial, social, emotional and functional wellbeing. A scale from 0 to 4 is used with 0= not at all, 1= a little bit, 2=somewhat, 3=quite a bit, 4=very much.

    Time frame: Screening and Week 8

  19. Life quality in children

    PEDS-QL for paediatric patients (\<18 years) at Screening and Week 8 to evaluate life quality in children. The patients and /or their parents have to answer questions about pain and hurt, fatigue and sleep, nausea, worry, Nutrition, thinking and communication. A scale from 0 to 4 is used with 0=never a Problem, 1=almost never a problem, 2= sometimes a problem, 3=often a problem, 4= almost always a problem.

    Time frame: Screening and Week 8

  20. Effect on the patient's T-cell phenotype in vivo

    T-cell phenotyping, samples taken at Screening, Day 0 and each visit from Day 7 to Week 15 after treatment.

    Time frame: Screening until Week 15

  21. Effect on the patient's number of expanded T cells

    Analysis of virus-specific T cells: frequencies of in vivo expanded virus-specific T cells in peripheral blood samples taken at Screening, Day 0, Day 7 to Week 15 after treatment.

    Time frame: Screening until Week 15

  22. Quality of the IMP and performance of the CliniMACS® Prodigy

    Assessment of the cellular composition, in particular the percentage of IFN-gamma+ cells, in the IMP.

    Time frame: Before IMP release (between Screening and Day 0)

  23. Evaluation of the drop-out rate

    Drop-out rate at Day 0 and reasons for drop-out.

    Time frame: at Day 0 (planned treatment day)

  24. Time from inclusion to administration of the IMP

    Number of days from Screening to Day 0 (day of IMP transfer) to evaluate the required time frame.

    Time frame: Screening until Day 0 (treatment day)

  25. Adverse events

    Documentation of incidence, severity and type of adverse events from Day 0 to Week 8 and serious adverse events throughout the study to evaluate safety.

    Time frame: 15 weeks

  26. Physical examination

    Physical examinations will be conducted to identify possible clinically significant pathologies. These findings will be recorded at each visit. The Karnofsky/Lansky index will be included in the physical examination at Screening and at Week 8 only.

    Time frame: Screening to Week 8

  27. Vital Sign - blood pressure

    supine systolic and diastolic blood preasure in mm Hg

    Time frame: Screening to Week 8

  28. Vital Signs - heart rate

    The resting heart rate in beats/min

    Time frame: Screening to Week 8

  29. Vital Signs - body temperature

    Body temperature in °C (aural)

    Time frame: Screening to Week 8

  30. Vital Signs - body weight

    body weight in kg

    Time frame: Screening to Week 8

  31. Vital Signs - respiratory rate

    respiratory rate in breaths/min.

    Time frame: Screening to Week 8

  32. Incidence of abnormal laboratory values

    haemoglobin, leukocytes, thrombocytes, dirfferential blood count (neutrophil granulocytes, lymphocytes, monocytes and easinophil granulocytes), total and conjugated Bilirubin, C reactive Protein (CRP), creatinine, Alanin aminotransferase (ALT), Aspartate aminotransferase (AST), Gamma glutamyl Transferase (GGT), Lactate Dehydrase (LDH), Urea. A list of normal ranges will be provided from each site.

    Time frame: Screening to Week 8

  33. Concomitant medication until Week 8

    All concomitant medication will be recorded from Screening until Week 8. The generic name, indication, route of administration, dose/ unit, start and stop date or ongoing, way of application will be documented.

    Time frame: 8 weeks after treatment

  34. Concomitant medication until Week 15

    During follow-up Week 15, only antiviral therapy, immunosuppression and SAE-related concomitant medication as well as chemotherapy will be documented. The generic name, indication, route of administration, dose/ unit, start and stop date or ongoing, way of application will be documented. Cellular treatment also has to be documented as concomitant medication.

    Time frame: 15 weeks after treatment

07

Study locations

33 of 33 sites recruiting
  • Institut Jules Bordet (JBI)
    Brussels, 1000, Belgium
    Recruiting
  • UZ Brussel
    Brussels, 1090, Belgium
    Recruiting
  • Ghent Universal Hospital (UZG)
    Ghent, 9000, Belgium
    Recruiting
  • UZ Leuven
    Leuven, 3000, Belgium
    Recruiting
  • Université de Liège (ULG)
    Liège, 4000, Belgium
    Recruiting
  • Hôpital Jeanne de Flandre, CHU Lille
    Lille, 59037, France
    Recruiting
  • Institut d'Hématologie et Oncologie Pédiatrique (IHOPe)
    Lyon, 69008, France
    Recruiting
  • Centre Hospitalier Régional Universitaire de Nancy (CHRU)
    Nancy, 54035, France
    Recruiting
  • Hôpital de la Pitie-Salpêtrière
    Paris, 75013, France
    Recruiting
  • Hôpital Necker - Enfants Malades
    Paris, 75015, France
    Recruiting
  • Hôpital Robert Debré
    Paris, 75019, France
    Recruiting
  • Charité Berlin (Campus Virchow-Klinikum) - Klinik für Pädiatrie mit Schwerpunkt Onkologie und Hämatologie
    Berlin, 13353, Germany
    Recruiting
  • Universitätsklinikum Dresden
    Dresden, 01307, Germany
    Recruiting
  • Universitätsklinikum Düsseldorf - Klinik für Kinder-Onkologie, -Hämatologie und klinische Immunologie
    Düsseldorf, 40225, Germany
    Recruiting
  • Universitätsklinikum Essen - Pädiatrische Hämatologie-Onkologie
    Essen, 45147, Germany
    Recruiting
  • Universitätsklinikum Freiburg - Klinik für Pädiatrische Hämatologie und Onkologie
    Freiburg im Breisgau, 79106, Germany
    Recruiting
  • Medizinische Hochschule Hannover - Zentrum für Kinderheilkunde und Jugendmedizin
    Hanover, 30625, Germany
    Recruiting
  • Universitäsklinikum Leipzig - Medizinische Klinik und Poliklinik I
    Leipzig, 04103, Germany
    Recruiting
  • LMU Klinikum - Dr. v. Haunersches Kinderspital
    Munich, 80337, Germany
    Recruiting
    • Tobias Feuchtinger, Prof. · Contactinfo@trace-study.de
    • Tobias Feuchtinger, Prof. · Principal investigator
  • Klinikum rechts der Isar der Technischen Universität - Kinderklinik Schwabing
    Munich, 80804, Germany
    Recruiting
  • LMU Klinikum - Medizinische Klinik und Poliklinik III
    München, 81377, Germany
    Recruiting
  • Klinikum rechts der Isar der Technischen Universität - Klinik und Poliklinik für Innere Medizin III
    München, 81675, Germany
    Recruiting
  • Universitätsklinikum Regensburg - Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
    Regensburg, 93053, Germany
    Recruiting
  • Universitätsklinikum Tübingen, Center for Pediatric Clinical Studies (CPCS)
    Tübingen, 72076, Germany
    Recruiting
  • Universitätsklinikum Würzburg - Medizinische Klinik und Poliklinik II & Zentrum Innere Medizin (ZIM)
    Würzburg, 97080, Germany
    Recruiting
  • Universitätsklinikum Würzburg - Pädiatrische Hämatologie, Onkologie und Stammzelltransplantation
    Würzburg, 97080, Germany
    Recruiting
    • Matthias Wölfl, Prof. · ContactWoelfl_M@kw.de
    • Matthias Wölfl, Prof. · Principal investigator
  • Ospedale Pediatrico Bambino Gesù (OPBG)
    Rome, 00165, Italy
    Recruiting
  • Ospedale Infantile Regina Margherita - Oncoematologie Pediatrica
    Turin, 10126, Italy
    Recruiting
  • Leiden University Medical Centre (LUMC) - Department of Hematology
    Leiden, 2333, Netherlands
    Recruiting
    • Peter van Balen, Dr. · ContactP.van_Balen@lumc.nl
    • Peter van Balen, Dr. · Principal investigator
  • Vall d'Hebron Institute of Oncology (VHIO)
    Barcelona, 119-129, Spain
    Recruiting
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
  • Hospital Virgen del Rocío
    Seville, 41013, Spain
    Recruiting
  • Hospital Universitario Politécnico La Fe
    Valencia, 46026, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2019 (actual). Primary completion is estimated for Mar 2028, 103 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2021
First posted
Apr 6, 2021
StartActual
Aug 27, 2019
Primary completionEst.
Mar 2028
CompletionEst.
Sep 2028
Last update
Jul 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04832607
Lead sponsor
Tobias Feuchtinger
Collaborators
European Commission, Simbec-Orion Group Ltd, Merthyr Tydfil, UK, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, Leiden University Medical Center, LUMC, Leiden, The Netherlands, Central Hospital, Nancy, France, University Hospital, Ghent, Ospedale Pediatrico Bambino Gesù, OPBG, Rome, Italy, Newcastle University, Vall d'Hebron Institute of Oncology
Responsible party
Tobias Feuchtinger (Prof. Dr. med Tobias Feuchtinger, University Hospital Freiburg) — Sponsor-investigator
First posted
Apr 6, 2021
Start date
Aug 27, 2019
Primary completion
Mar 2028 (estimated)
Completion
Sep 2028 (estimated)
Last update
Jul 18, 2025

Study contacts

Tobias Feuchtinger, Prof
Contact
kjk.trace-study@uniklinik-freiburg.de
0049 (0)761 270 ext. 43641
Theresa Käuferle, Dr
Contact
kjk.trace-study@uniklinik-freiburg.de
0049 (0)761 270 ext. 43369
Tobias Feuchtinger, Prof
principal investigator · Medical Center - University of Freiburg

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion